MX394799B - Anticuerpos anti-il-33 y usos de los mismos. - Google Patents
Anticuerpos anti-il-33 y usos de los mismos.Info
- Publication number
- MX394799B MX394799B MX2019004863A MX2019004863A MX394799B MX 394799 B MX394799 B MX 394799B MX 2019004863 A MX2019004863 A MX 2019004863A MX 2019004863 A MX2019004863 A MX 2019004863A MX 394799 B MX394799 B MX 394799B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- bind
- agents
- useful
- methods
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 102000045906 human IL33 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a anticuerpos que se unen a IL-33 humana y la neutralizan, y métodos para usar los mismos, tales anticuerpos son útiles como agentes para el tratamiento de condiciones asociadas con enfermedad alérgica que incluye el tratamiento de dermatitis atópica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662414258P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/058020 WO2018081075A1 (en) | 2016-10-28 | 2017-10-24 | Anti-il-33 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019004863A MX2019004863A (es) | 2019-08-12 |
| MX394799B true MX394799B (es) | 2025-03-24 |
Family
ID=60263117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004863A MX394799B (es) | 2016-10-28 | 2017-10-24 | Anticuerpos anti-il-33 y usos de los mismos. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10501536B2 (es) |
| EP (1) | EP3532499B1 (es) |
| JP (1) | JP6830533B2 (es) |
| KR (1) | KR102266144B1 (es) |
| CN (1) | CN109863173B (es) |
| AR (1) | AR109948A1 (es) |
| AU (1) | AU2017351183B2 (es) |
| BR (1) | BR112019005139A2 (es) |
| CA (1) | CA3039232C (es) |
| CL (1) | CL2019001043A1 (es) |
| CO (1) | CO2019003047A2 (es) |
| CR (1) | CR20190179A (es) |
| CY (1) | CY1124360T1 (es) |
| DK (1) | DK3532499T3 (es) |
| EA (1) | EA201990778A1 (es) |
| EC (1) | ECSP19029758A (es) |
| ES (1) | ES2878037T3 (es) |
| HR (1) | HRP20211221T1 (es) |
| HU (1) | HUE055621T2 (es) |
| IL (1) | IL265689B2 (es) |
| JO (1) | JOP20190093A1 (es) |
| LT (1) | LT3532499T (es) |
| MA (1) | MA46619B1 (es) |
| MD (1) | MD3532499T2 (es) |
| MX (1) | MX394799B (es) |
| PE (1) | PE20191045A1 (es) |
| PH (1) | PH12019500929A1 (es) |
| PL (1) | PL3532499T3 (es) |
| PT (1) | PT3532499T (es) |
| RS (1) | RS62120B1 (es) |
| SI (1) | SI3532499T1 (es) |
| SM (1) | SMT202100442T1 (es) |
| TN (1) | TN2019000086A1 (es) |
| TW (2) | TWI676680B (es) |
| UA (1) | UA121293C2 (es) |
| WO (1) | WO2018081075A1 (es) |
| ZA (1) | ZA201901935B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
| JP7551744B2 (ja) | 2019-10-15 | 2024-09-17 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株 |
| KR20220092927A (ko) | 2019-11-04 | 2022-07-04 | 메디뮨 리미티드 | 신장 장애를 치료하기 위한 항 il-33 치료제 |
| CA3158323A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
| CN113214395A (zh) * | 2020-01-21 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 抗st2抗体及其应用 |
| US20230110203A1 (en) | 2020-03-13 | 2023-04-13 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| EP4118114A1 (en) | 2020-03-13 | 2023-01-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| BR112022019937A2 (pt) | 2020-04-06 | 2022-12-13 | Medimmune Ltd | Tratamento de síndrome do desconforto respiratório agudo com antagonistas de ligação de eixo de il-33 |
| US20230174638A1 (en) | 2020-05-11 | 2023-06-08 | Medimmune Limited | Formulations of anti-il-33 antibodies |
| CN111620948B (zh) * | 2020-06-10 | 2022-04-08 | 南京赛新生物科技有限公司 | 针对il-33的抗体 |
| CN113603775B (zh) | 2021-09-03 | 2022-05-20 | 江苏荃信生物医药股份有限公司 | 抗人白介素-33单克隆抗体及其应用 |
| TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
| EP4573121A1 (en) | 2022-08-19 | 2025-06-25 | MedImmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
| WO2025114862A1 (en) * | 2023-11-27 | 2025-06-05 | Glaxosmithkline Intellectual Property Development Limited | Il-33 binding antibodies |
| WO2025120567A1 (en) | 2023-12-07 | 2025-06-12 | Medimmune Limited | Method of treatment of asthma |
| WO2025210099A1 (en) | 2024-04-04 | 2025-10-09 | Medimmune Limited | Method of treatment and selecting a subject |
| WO2025242618A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Bronchiectasis treatment |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| US8119771B2 (en) | 2007-04-26 | 2012-02-21 | The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | Products for altering IL-33 activity and methods thereof |
| CA2686683A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | Il-33 in inflammatory disease |
| US20120263709A1 (en) * | 2009-09-10 | 2012-10-18 | Schering Corporation | Use of il-33 antagonists to treat fibrotic diseases |
| US8785153B2 (en) * | 2011-02-23 | 2014-07-22 | Hoffmann-La Roche, Inc. | Antibodies against human IL33R and uses thereof |
| FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| FI3088517T3 (fi) * | 2013-12-26 | 2023-11-30 | Mitsubishi Tanabe Pharma Corp | Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine |
| WO2015106080A2 (en) * | 2014-01-10 | 2015-07-16 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| EP3134120B1 (en) * | 2014-04-21 | 2024-01-24 | The Children's Hospital of Philadelphia | Compositions and methods for treating cytokine-related disorders |
| MX2017006094A (es) * | 2014-11-10 | 2017-07-19 | Genentech Inc | Anticuerpos anti-interleucina-33 y sus usos. |
| SMT202100086T1 (it) | 2015-03-31 | 2021-03-15 | Medimmune Ltd | Una nuova forma di il33, forme mutate di il33, anticorpi, saggi e metodi per usare gli stessi |
| MX2018008732A (es) | 2016-01-14 | 2018-12-06 | Anaptysbio Inc | Inhibicion de la reaccion alergica usando un inhibidor de il-33. |
| JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
-
2017
- 2017-06-16 JO JOP/2019/0093A patent/JOP20190093A1/ar unknown
- 2017-10-13 AR ARP170102863A patent/AR109948A1/es unknown
- 2017-10-13 TW TW107143762A patent/TWI676680B/zh active
- 2017-10-13 TW TW106135006A patent/TWI647238B/zh active
- 2017-10-24 PL PL17794593T patent/PL3532499T3/pl unknown
- 2017-10-24 TN TNP/2019/000086A patent/TN2019000086A1/en unknown
- 2017-10-24 CN CN201780065572.XA patent/CN109863173B/zh active Active
- 2017-10-24 EP EP17794593.8A patent/EP3532499B1/en active Active
- 2017-10-24 RS RS20210875A patent/RS62120B1/sr unknown
- 2017-10-24 EA EA201990778A patent/EA201990778A1/ru unknown
- 2017-10-24 MD MDE20190980T patent/MD3532499T2/ro unknown
- 2017-10-24 HU HUE17794593A patent/HUE055621T2/hu unknown
- 2017-10-24 ES ES17794593T patent/ES2878037T3/es active Active
- 2017-10-24 JP JP2019522272A patent/JP6830533B2/ja active Active
- 2017-10-24 AU AU2017351183A patent/AU2017351183B2/en active Active
- 2017-10-24 KR KR1020197012190A patent/KR102266144B1/ko active Active
- 2017-10-24 CR CR20190179A patent/CR20190179A/es unknown
- 2017-10-24 WO PCT/US2017/058020 patent/WO2018081075A1/en not_active Ceased
- 2017-10-24 HR HRP20211221TT patent/HRP20211221T1/hr unknown
- 2017-10-24 PT PT177945938T patent/PT3532499T/pt unknown
- 2017-10-24 UA UAA201903400A patent/UA121293C2/uk unknown
- 2017-10-24 CA CA3039232A patent/CA3039232C/en active Active
- 2017-10-24 SM SM20210442T patent/SMT202100442T1/it unknown
- 2017-10-24 MA MA46619A patent/MA46619B1/fr unknown
- 2017-10-24 LT LTEP17794593.8T patent/LT3532499T/lt unknown
- 2017-10-24 MX MX2019004863A patent/MX394799B/es unknown
- 2017-10-24 SI SI201730830T patent/SI3532499T1/sl unknown
- 2017-10-24 BR BR112019005139A patent/BR112019005139A2/pt unknown
- 2017-10-24 US US15/791,641 patent/US10501536B2/en active Active
- 2017-10-24 PE PE2019000838A patent/PE20191045A1/es unknown
- 2017-10-24 IL IL265689A patent/IL265689B2/en unknown
- 2017-10-24 DK DK17794593.8T patent/DK3532499T3/da active
-
2019
- 2019-03-28 CO CONC2019/0003047A patent/CO2019003047A2/es unknown
- 2019-03-28 ZA ZA201901935A patent/ZA201901935B/en unknown
- 2019-04-16 CL CL2019001043A patent/CL2019001043A1/es unknown
- 2019-04-25 PH PH12019500929A patent/PH12019500929A1/en unknown
- 2019-04-26 EC ECSENADI201929758A patent/ECSP19029758A/es unknown
- 2019-10-25 US US16/663,561 patent/US10913793B2/en active Active
-
2021
- 2021-07-26 CY CY20211100672T patent/CY1124360T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394799B (es) | Anticuerpos anti-il-33 y usos de los mismos. | |
| CY1125327T1 (el) | Anti-pd-1 αντισωματα και συνθεσεις | |
| MX394103B (es) | Anticuerpos anti-angptl8 y usos de estos. | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2024010175A (es) | Moleculas de anticuerpo contra april y usos de las mismas. | |
| MX391051B (es) | Anticuerpos anti-cd47 y usos de los mismos. | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| MX377712B (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| CL2017000545A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| CL2018000728A1 (es) | Anticuerpos anti-cd19 humano humanizados y métodos de utilización | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| EA201791884A1 (ru) | Химерные антигенные рецепторы против dll3 и способы применения | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
| EA201691473A1 (ru) | Биспецифические анти-il-13/il-17 антитела и их применение | |
| MX375032B (es) | Proteínas de unión y métodos para utilizarlas. | |
| BR112018067525A2 (pt) | anticorpos tendo especificidade para o btla e seus usos | |
| EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| BR112017009764A2 (pt) | anticorpos biespecíficos e métodos de uso em oftalmologia | |
| BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
| AR101486A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso |